A First-in-Human Phase 1 Study of Abbv-319, an Antibody-Drug Conjugate Composed of a CD19 Antibody Linked to a Potent Proprietary Glucocorticoid Receptor Modulator, in Patients with Relapsed or Refractory B-Cell Malignancies

医学 抗体 抗体-药物偶联物 内科学 滤泡性淋巴瘤 慢性淋巴细胞白血病 B细胞 淋巴瘤 肿瘤科 癌症研究 免疫学 药理学 白血病 单克隆抗体
作者
Moshe Levy,Carl Gustafson,James W. Purcell,Kevin J. Freise,Wissam Assaily,Deanna J. Brackman,William R. Henner,Michael A. McDevitt,John Kuruvilla
出处
期刊:Blood [Elsevier BV]
卷期号:140 (Supplement 1): 3746-3747
标识
DOI:10.1182/blood-2022-166809
摘要

Background Systemic glucocorticosteroids (ie, glucocorticoid receptor modulators [GRMs]) show robust monotherapy activity against B-cell malignancies at high doses; however, they may be accompanied by steroid-associated toxicities that limit dosing. CD19 is a marker essential for B-cell proliferation and has high expression across B-cell malignancies including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL). ABBV-319 is a CD19-GRM antibody-drug conjugate (ADC) composed of an optimized high-affinity immunoglobulin G1 antibody conjugated to a potent proprietary glucocorticosteroid payload. ABBV-319 takes advantage of both enhanced antibody-dependent cellular cytotoxicity (via afucosylation) and targeted GRM payload delivery to maximize anticancer activity while lowering the risk of systemic steroid toxicities. Preclinically, ABBV-319 demonstrates sustained antitumor efficacy in models of human B-cell malignancies that compares favorably with approved therapeutics. This phase 1 study evaluates safety and clinical activity of ABBV-319 monotherapy in patients with relapsed or refractory (R/R) B-cell malignancies. Methods This is a phase 1, first-in-human, open-label, dose-escalation, dose-expansion, biomarker/pharmacodynamic (PD) study in patients aged ≥18 years with R/R B-cell malignancies. Key eligibility criteria include measurable disease and Eastern Cooperative Oncology Group performance status of 0 or 1. In addition, patients must meet predefined criteria for adrenal, bone marrow, kidney, and liver function, coagulation parameter levels, and hemoglobin A1c levels (dose escalation only) during screening. The primary objectives are to evaluate safety, tolerability, pharmacokinetics (PK), and immunogenicity of ABBV-319 and identify a recommended phase 2 dose (RP2D). The secondary objective is to evaluate the efficacy of ABBV-319 in patients with R/R DLBCL, FL, and CLL. Exploratory objectives include evaluating the effect of ABBV-319 on QT prolongation and evaluating PD and predictive biomarkers. This study will be conducted in 2 parts - dose escalation (Part 1) and dose expansion (Part 2). Part 1 aims to determine the RP2D for ABBV-319 following a Bayesian optimal interval design, with a maximum of 2-fold increments that reduce as the dose increases. RP2D will be determined on the basis of all the data collected in Part 1 including safety, tolerability, PK, PD, and efficacy, if available. Part 2 will further evaluate ABBV-319 at the RP2D in 3 separate subtypes of B-cell malignancies - DLBCL, FL, and CLL. A total of 114 patients are planned to be enrolled - 54 patients with various R/R B-cell malignancies in Part 1, and 60 patients in Part 2 (20 patients included for each R/R B-cell malignancy subtype: DLBCL, FL, and CLL). ABBV-319 will be administered intravenously until disease progression, intolerable toxicity, or other study discontinuation criteria are met, for a maximum of ~24 months from the last patient enrolled. Safety assessments include adverse event monitoring (per National Cancer Institute Common Terminology Criteria for Adverse Events v5.0), physical examinations, vital sign measurements, and clinical laboratory testing. Dose-limiting toxicities will be assessed. PK parameters including maximum observed serum/plasma concentration (Cmax), time to Cmax, terminal plasma elimination half-life, and area under the serum/plasma concentration-time curve will be analyzed using noncompartmental methods for ABBV-319 total antibody, ADC, and unconjugated GRM payload. Antidrug antibodies (ADAs) and neutralizing ADAs may also be determined, as appropriate. Efficacy will be evaluated in terms of response per disease-specific criteria (including International Workshop on Chronic Lymphocytic Leukemia, International Workshop on Waldenstrom's Macroglobulinemia, and Lugano classification). Duration of response, time to response, progression-free survival, and overall survival will be evaluated per Kaplan-Meier analysis. QT prolongation, PD, and biomarker data will be assessed as changes from baseline and may be summarized for each scheduled postbaseline visit.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
chilit完成签到 ,获得积分10
1秒前
wei完成签到 ,获得积分10
1秒前
pppcpppdpppy完成签到,获得积分10
2秒前
凌泉完成签到 ,获得积分10
5秒前
苏格拉底嵩先生关注了科研通微信公众号
5秒前
xixilulixiu完成签到 ,获得积分0
6秒前
嘻嘻哈哈的应助被困困采纳,获得10
7秒前
sevakdumpling完成签到 ,获得积分10
8秒前
学霸业的应助被liugm采纳,获得10
8秒前
青旭流觞完成签到,获得积分10
9秒前
哈哈哈曲奇完成签到 ,获得积分10
11秒前
1234完成签到 ,获得积分10
13秒前
欢喜的听南完成签到,获得积分10
14秒前
14秒前
15秒前
芭乐王子完成签到 ,获得积分10
16秒前
执着书瑶完成签到,获得积分10
19秒前
27秒前
香蕉觅云的应助被hui采纳,获得10
27秒前
研友_西门孤晴完成签到,获得积分10
27秒前
falling_learning完成签到 ,获得积分10
29秒前
孟子完成签到 ,获得积分10
29秒前
32秒前
冷傲山彤完成签到,获得积分10
33秒前
33秒前
i2stay完成签到,获得积分0
34秒前
端庄代荷完成签到 ,获得积分10
40秒前
Firsterchao完成签到,获得积分0
40秒前
41秒前
独自开朗完成签到 ,获得积分10
41秒前
舒心的访云完成签到 ,获得积分10
45秒前
魔幻友菱完成签到 ,获得积分10
46秒前
没啥鱼丸完成签到 ,获得积分10
46秒前
夜话风陵杜完成签到 ,获得积分0
49秒前
DH完成签到 ,获得积分10
50秒前
独特珩完成签到,获得积分10
55秒前
56秒前
57秒前
57秒前
kjdgahdg发布了新的文献求助10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159091
求助须知:如何正确求助?哪些是违规求助? 9554590
关于积分的说明 21719629
捐赠科研通 7748753
什么是DOI,文献DOI怎么找? 3427139
关于科研通互助平台的介绍 2552066
邀请新用户注册赠送积分活动 2471426